Overview

A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma

Status:
Terminated

Trial end date:
2010-11-04

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine the safety and tolerability of SRT501 (5.0 g) with or without concurrent bortezomib administration, when administered once daily in 21 day cycles, in male and female subjects with Multiple Myeloma. The purpose is also to define objective response (ORR, CR, PR, MR, SD) and time to progression (TTP) of SRT501 with or without concurrent bortezomib administered concurrently in male and female subjects with Multiple Myeloma. In addition, 15 subjects will participate in a sub-study to assess the pharmacokinetics of SRT501.

Phase:

Phase 2

Details

Lead Sponsor:

Sirtris, a GSK Company

Collaborator:

GlaxoSmithKline

Treatments:

Bortezomib
Resveratrol